Affimed NV Financials

AFMD Stock  USD 2.62  0.02  0.76%   
Based on the key indicators related to Affimed NV's liquidity, profitability, solvency, and operating efficiency, Affimed NV is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December. At present, Affimed NV's Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 28.4 M, whereas Total Stockholder Equity is forecasted to decline to about 45.3 M. Key indicators impacting Affimed NV's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio4.763.2496
Way Up
Very volatile
Investors should never underestimate Affimed NV's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Affimed NV's cash flow, debt, and profitability to make informed and accurate decisions about investing in Affimed NV.

Net Income

(100.64 Million)

  
Understanding current and past Affimed NV Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Affimed NV's financial statements are interrelated, with each one affecting the others. For example, an increase in Affimed NV's assets may result in an increase in income on the income statement.
Please note, the presentation of Affimed NV's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Affimed NV's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Affimed NV's management manipulating its earnings.

Affimed NV Stock Summary

Affimed NV competes with Pieris Pharmaceuticals, ADC Therapeutics, Agenus, X4 Pharmaceuticals, and Terns Pharmaceuticals. Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany. Affimed NV operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 197 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINNL0010872420
CUSIPN01045108 N01045207
LocationGermany
Business AddressGottlieb-Daimler-Strae 2, Mannheim,
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.affimed.com
Phone49 621 560030
CurrencyUSD - US Dollar

Affimed NV Key Financial Ratios

Affimed NV Key Balance Sheet Accounts

201920202021202220232024 (projected)
Total Assets112.4M175.7M225.1M200.5M97.2M105.8M
Other Current Liab24.3M517K58.5M46.2M53.1M55.8M
Other Liab37.5M38.0M36.0M7.2M8.3M15.7M
Net Debt(92.0M)(145.6M)(178.9M)(172.1M)(19.2M)(20.1M)
Retained Earnings(234.5M)(275.9M)(333.4M)(430.2M)(536.1M)(509.3M)
Accounts Payable10.7M11.4M18.9M19.1M18.9M10.3M
Cash95.2M146.9M197.6M190.3M38.5M36.6M
Long Term Debt278K231K17.1M11.7M6.3M6.0M
Net Receivables1.5M2.4M4.8M2.7M5.3M5.6M
Inventory296K246K421K628K463K315.3K
Total Liab73.7M103.7M89.2M47.6M39.4M60.4M
Total Current Assets105.9M150.8M206.4M196.1M84.2M98.5M
Intangible Assets137K1.7M1.6M58K25K23.8K
Common Stock762K983K1.2M1.5M1.5M1.6M
Net Tangible Assets40.1M38.5M70.3M134.3M154.5M162.2M
Short Long Term Debt2.1M92K580K5.9M5.8M8.3M
Short Term Debt2.6M584K1.3M6.3M6.4M3.4M
Other Current Assets8.9M1.3M3.5M(2.7M)5.5M5.8M
Net Invested Capital41.1M72.3M153.6M170.5M70.0M92.9M
Net Working Capital70.7M83.8M141.8M161.4M58.3M98.1M

Affimed NV Key Income Statement Accounts

201920202021202220232024 (projected)
Interest Expense483K95K712K1.6M1.8M1.8M
Total Revenue21.4M28.4M40.4M41.4M8.3M7.9M
Gross Profit21.4M28.4M40.4M41.4M8.3M7.9M
Operating Income(32.4M)(34.7M)(64.0M)(88.1M)(106.7M)(101.3M)
Ebit(31.2M)(35.3M)(65.4M)(84.3M)(104.1M)(98.9M)
Research Development43.8M50.0M81.5M98.8M95.0M99.7M
Ebitda(31.0M)(34.2M)(64.0M)(81.5M)(102.4M)(97.3M)
Income Before Tax(32.4M)(41.4M)(57.5M)(86.0M)(105.9M)(100.6M)
Net Income(32.4M)(41.4M)(57.5M)(86.0M)(105.9M)(100.6M)
Income Tax Expense(20K)1K4K2K3K3.2K
Interest Income5K602K186K0.0509K534.5K
Tax Provision(20K)1K4K2K3K3.2K
Net Interest Income190K(6.6M)(1.1M)2.1M238K249.9K

Affimed NV Key Cash Accounts

201920202021202220232024 (projected)
Change To Inventory(36K)50K(175K)(207K)100K105K
Change In Cash405K51.6M50.8M(7.3M)(151.8M)(144.2M)
Free Cash Flow(30.5M)(19.8M)(90.4M)(105.6M)(114.0M)(108.3M)
Depreciation906K1.1M1.3M2.9M1.7M984.3K
Other Non Cash Items384K6.9M(7.4M)(2.8M)(4.6M)(4.4M)
Capital Expenditures1.5M440K3.9M696K3.7M3.9M
Net Income(32.4M)(41.4M)(57.5M)(86.0M)(105.9M)(100.6M)
End Period Cash Flow95.2M146.9M197.6M190.3M38.5M36.6M
Investments4.3M8.4M(3.9M)5.6M(36.1M)(34.3M)
Net Borrowings(2.9M)(3.1M)(2.6M)16.8M19.4M20.3M
Change To Netincome1.9M2.9M10.3M4.4M5.1M2.9M

Affimed Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Affimed NV's current stock value. Our valuation model uses many indicators to compare Affimed NV value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Affimed NV competition to find correlations between indicators driving Affimed NV's intrinsic value. More Info.
Affimed NV is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Affimed NV's Return On Equity is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Affimed NV by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Affimed NV Systematic Risk

Affimed NV's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Affimed NV volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on Affimed NV correlated with the market. If Beta is less than 0 Affimed NV generally moves in the opposite direction as compared to the market. If Affimed NV Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Affimed NV is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Affimed NV is generally in the same direction as the market. If Beta > 1 Affimed NV moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Affimed NV Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Affimed NV's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Affimed NV growth as a starting point in their analysis.

Price Earnings To Growth Ratio

(0.0436)

At present, Affimed NV's Price Earnings To Growth Ratio is projected to increase slightly based on the last few years of reporting.

Affimed NV November 25, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Affimed NV help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Affimed NV. We use our internally-developed statistical techniques to arrive at the intrinsic value of Affimed NV based on widely used predictive technical indicators. In general, we focus on analyzing Affimed Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Affimed NV's daily price indicators and compare them against related drivers.

Complementary Tools for Affimed Stock analysis

When running Affimed NV's price analysis, check to measure Affimed NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Affimed NV is operating at the current time. Most of Affimed NV's value examination focuses on studying past and present price action to predict the probability of Affimed NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Affimed NV's price. Additionally, you may evaluate how the addition of Affimed NV to your portfolios can decrease your overall portfolio volatility.
Global Correlations
Find global opportunities by holding instruments from different markets
Commodity Directory
Find actively traded commodities issued by global exchanges